• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚乙二醇化重组人粒细胞集落刺激因子对恶性肿瘤患者淋巴细胞及白细胞的影响。

Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor.

作者信息

Zhao Tong, Wang Yuejun, Zhou Deqing, Zhang Weike

机构信息

Department of Oncology, The Eighth People's Hospital of Jinan, No. 68, Xinxing Road, Gangcheng District, Jinan 271104, P.R. China.

Department of Medical Administration, Jinan Gangcheng District Health Bureau, Jinan 270016, P.R. China.

出版信息

Open Life Sci. 2023 Apr 12;18(1):20220590. doi: 10.1515/biol-2022-0590. eCollection 2023.

DOI:10.1515/biol-2022-0590
PMID:37070077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10105549/
Abstract

We investigated the effect of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) on lymphocytes and white blood cells of patients with malignant tumors. After PEG-rhG-CSF treatment, the count of lymphocytes increased in 66 cases, remained unchanged in 2 cases, and decreased in 20 cases. The difference in lymphocyte count before and after treatment was statistically significant ( < 0.001). White blood cell changes were positively correlated with lymphocyte changes ( = 0.36, = 0.001). In the subgroup with increased white blood cells ( = 80), there were 62 cases with increased lymphocytes, 1 case with unchanged lymphocytes, and 17 cases with decreased lymphocytes after PEG-rhG-CSF treatment. There was significant difference in the count of lymphocytes and white blood cells ( < 0.001). In the subgroup with 6 mg of PEG-rhG-CSF ( = 66) and the subgroup with 3 mg of PEG-rhG-CSF ( = 22), the changes of white blood cell and lymphocyte counts before and after treatment were statistically significant ( < 0.001). The two were positively correlated in the 6 mg PEG-rhG-CSF subgroup, with correlation coefficient = 0.34 ( = 0.002). PEG-rhG-CSF can increase the count of lymphocytes and white blood cells in patients with malignant tumors, and the increase of lymphocytes is positively correlated with the increase of white blood cells.

摘要

我们研究了聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)对恶性肿瘤患者淋巴细胞和白细胞的影响。PEG-rhG-CSF治疗后,66例患者淋巴细胞计数增加,2例不变,20例减少。治疗前后淋巴细胞计数差异有统计学意义(<0.001)。白细胞变化与淋巴细胞变化呈正相关(=0.36,=0.001)。在白细胞增加的亚组(=80)中,PEG-rhG-CSF治疗后有62例淋巴细胞增加,1例淋巴细胞不变,17例淋巴细胞减少。淋巴细胞和白细胞计数有显著差异(<0.001)。在PEG-rhG-CSF 6mg亚组(=66)和PEG-rhG-CSF 3mg亚组(=22)中,治疗前后白细胞和淋巴细胞计数变化有统计学意义(<0.001)。在PEG-rhG-CSF 6mg亚组中两者呈正相关,相关系数=0.34(=0.002)。PEG-rhG-CSF可增加恶性肿瘤患者的淋巴细胞和白细胞计数,且淋巴细胞增加与白细胞增加呈正相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc11/10105549/76919ab1af42/j_biol-2022-0590-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc11/10105549/3624d42a0707/j_biol-2022-0590-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc11/10105549/76919ab1af42/j_biol-2022-0590-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc11/10105549/3624d42a0707/j_biol-2022-0590-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc11/10105549/76919ab1af42/j_biol-2022-0590-fig002.jpg

相似文献

1
Effects of pegylated recombinant human granulocyte colony-stimulating factor on lymphocytes and white blood cells of patients with malignant tumor.聚乙二醇化重组人粒细胞集落刺激因子对恶性肿瘤患者淋巴细胞及白细胞的影响。
Open Life Sci. 2023 Apr 12;18(1):20220590. doi: 10.1515/biol-2022-0590. eCollection 2023.
2
Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.聚乙二醇化重组人粒细胞集落刺激因子调节小细胞肺癌患者的免疫状态。
Thorac Cancer. 2020 Mar;11(3):713-722. doi: 10.1111/1759-7714.13322. Epub 2020 Feb 5.
3
Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.预防性应用粒细胞集落刺激因子对早期乳腺癌患者化疗后外周血白细胞及中性粒细胞计数水平的影响:一项回顾性队列研究
Front Oncol. 2022 Apr 25;12:777602. doi: 10.3389/fonc.2022.777602. eCollection 2022.
4
Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia.聚乙二醇化重组人粒细胞集落刺激因子治疗同步放化疗所致Ⅳ度中性粒细胞减少症患者疗效的临床观察
Exp Ther Med. 2015 Mar;9(3):761-765. doi: 10.3892/etm.2014.2160. Epub 2014 Dec 30.
5
[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].聚乙二醇化重组人粒细胞集落刺激因子治疗化疗所致中性粒细胞减少症:一项多中心随机对照II期临床研究
Zhonghua Yi Xue Za Zhi. 2006 Dec 26;86(48):3414-9.
6
[Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].静脉注射聚乙二醇化重组人粒细胞集落刺激因子的I期临床试验
Ai Zheng. 2006 Apr;25(4):495-500.
7
Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.聚乙二醇化重组人粒细胞集落刺激因子两种制剂在健康中国受试者中的药代动力学和药效学:一项开放标签、随机、平行设计的生物利用度研究。
Clin Pharmacol Drug Dev. 2021 Mar;10(3):291-298. doi: 10.1002/cpdd.819. Epub 2020 Jun 21.
8
Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.聚乙二醇化重组人粒细胞集落刺激因子 3mg 支持肺癌化疗的疗效和安全性。
Thorac Cancer. 2022 Jan;13(1):117-125. doi: 10.1111/1759-7714.14233. Epub 2021 Nov 17.
9
Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats.重组人粒细胞集落刺激因子对正常猫造血功能的影响。
Exp Hematol. 1991 Sep;19(8):759-67.
10
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.聚乙二醇化重组人粒细胞集落刺激因子治疗乳腺癌化疗后中性粒细胞减少症的随机对照临床试验。
Cancer Chemother Pharmacol. 2018 Oct;82(4):607-613. doi: 10.1007/s00280-018-3639-z. Epub 2018 Jul 24.

引用本文的文献

1
Formulation and In Vitro Characterization of Granulocyte-Colony-Stimulating-Factor-Loaded Liposomes: Future Prospective in Reproductive Medicine.负载粒细胞集落刺激因子的脂质体的制备及体外特性:生殖医学的未来展望
Int J Mol Sci. 2025 Mar 17;26(6):2689. doi: 10.3390/ijms26062689.

本文引用的文献

1
Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer.PEG-rhG-CSF 预防局部晚期宫颈癌患者放化疗引起中性粒细胞减少的疗效和安全性。
Biomol Biomed. 2023 Mar 16;23(2):310-316. doi: 10.17305/bjbms.2022.7859.
2
PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.PEG-rhG-CSF 用于预防非小细胞肺癌患者化疗后中性粒细胞减少症:一项多中心、前瞻性、随机研究。
Thorac Cancer. 2022 Sep;13(17):2429-2435. doi: 10.1111/1759-7714.14544. Epub 2022 Jul 20.
3
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
美国的化疗所致中性粒细胞减少症和发热性中性粒细胞减少症:一种需要驯服的负担?
Oncologist. 2022 Aug 5;27(8):625-636. doi: 10.1093/oncolo/oyac074.
4
Radiotherapy, chemotherapy, and heart disease.放射疗法、化学疗法与心脏病
Breast Cancer Res Treat. 2022 May;193(1):239-240. doi: 10.1007/s10549-022-06554-y. Epub 2022 Feb 28.
5
CD3CD4CD8 (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.CD3CD4CD8(双阴性)T 细胞在炎症、免疫紊乱和癌症中的作用。
Front Immunol. 2022 Feb 10;13:816005. doi: 10.3389/fimmu.2022.816005. eCollection 2022.
6
Cost-Effectiveness Analysis of PEG-rhG-CSF as Primary Prophylaxis to Chemotherapy-Induced Neutropenia in Women With Breast Cancer in China: Results Based on Real-World Data.聚乙二醇化重组人粒细胞集落刺激因子作为中国乳腺癌女性化疗所致中性粒细胞减少症一级预防的成本效益分析:基于真实世界数据的结果
Front Pharmacol. 2022 Feb 3;12:754366. doi: 10.3389/fphar.2021.754366. eCollection 2021.
7
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.纳武利尤单抗联合治疗晚期食管鳞癌。
N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
8
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?化疗联合单药/双药免疫疗法治疗非癌基因成瘾性晚期非小细胞肺癌:我们现状如何,又将走向何方?
Expert Rev Anticancer Ther. 2022 Feb;22(2):183-189. doi: 10.1080/14737140.2022.2026772. Epub 2022 Jan 20.
9
Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.免疫疗法失败——肺癌免疫疗法耐药的分子和免疫学起源。
Int J Mol Sci. 2021 Aug 21;22(16):9030. doi: 10.3390/ijms22169030.
10
A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)在宫颈癌同期放化疗中预防中性粒细胞减少症的临床研究。
BMC Cancer. 2021 Jun 2;21(1):661. doi: 10.1186/s12885-021-08364-9.